CagriSema, a weekly cagrilintide-plus-semaglutide shot, cut body weight by 20.4% vs 3.0% on placebo over 68 weeks in REDEFINE 1 (3,417 adults without diabetes), and 13.7% vs 3.4% in people with type 2 diabetes. It fell short of matching tirzepatide head to head. Novo Nordisk filed for FDA approval in December 2025; it is not approved yet.
CagriSema is a bet on two appetite pathways instead of one. It pairs cagrilintide, a long-acting amylin analog, with semaglutide, the familiar GLP-1 agonist, in a single weekly injection. The theory is complementary biology — amylin and GLP-1 suppress appetite through different mechanisms, so combining them might add up to more than either alone. The REDEFINE Phase 3 program is where that theory met data, and the result was more nuanced than the early hype.
The building blocks
Each half has its own evidence base. In a Phase 2 trial, cagrilintide alone produced dose-dependent weight loss in people with overweight or obesity, establishing amylin agonism as a viable weight-management lever.[1] A separate Phase 1b study showed the two could be co-administered safely with a pharmacokinetic and tolerability profile supporting a fixed-dose combination.[2] Those studies justified building the combination — but combination logic does not guarantee additive results, which is exactly what Phase 3 had to test.
REDEFINE 1: obesity without diabetes
REDEFINE 1 randomized adults with overweight or obesity (without type 2 diabetes) to CagriSema, its individual components, or placebo. Across 3,417 randomized participants, mean body weight fell 20.4 percent on CagriSema versus 3.0 percent on placebo at week 68, a 17.3-point difference (95% CI −18.1 to −16.6). Gastrointestinal side effects such as nausea, vomiting, diarrhea and constipation affected 79.6 percent of the CagriSema group versus 39.9 percent on placebo, mostly mild to moderate and transient.[3] The widely discussed wrinkle was that the topline figure landed below some pre-trial expectations — in part because many participants did not reach the highest target dose — which tempered the “step-change” narrative even as the absolute weight loss remained large and clinically meaningful. A secondary analysis from REDEFINE 1 also reported reductions in blood pressure with CagriSema (systolic −10.9 versus −2.8 mm Hg on placebo), consistent with the broader cardiometabolic effects seen across this drug class.[4]
REDEFINE 2: when type 2 diabetes is in the mix
REDEFINE 2 tested CagriSema in adults who had both overweight/obesity and type 2 diabetes — a population that typically loses less weight on incretin therapy. Across 1,206 randomized patients, mean body weight fell 13.7 percent on CagriSema versus 3.4 percent on placebo at week 68 — a 10.4-percentage-point difference (95% CI −11.2 to −9.5, p < 0.001) — alongside glycemic improvement: 73.5 percent of the CagriSema group reached an HbA1c of 6.5 percent or lower, against 15.9 percent on placebo.[5] That the effect held up in a diabetes population is a meaningful data point, even though the magnitude in such populations is generally more modest than in people without diabetes.
The honest caveats
A few things keep this precise. The tolerability profile is the GLP-1-class profile —gastrointestinal side effects were common and dose-dependent, and the share of participants reaching the top dose shaped the headline numbers. CagriSema does not yet have the long-term cardiovascular-outcomes evidence that anchors injectable semaglutide's case; REDEFINE measured weight and metabolic endpoints, not multi-year hard outcomes. On regulation, Novo Nordisk submitted CagriSema 2.4 mg/2.4 mg to the FDA for weight management in December 2025; as of October 2026 we found no FDA decision, so it is not an approved drug and cannot be legally prescribed as CagriSema.[7] A later head-to-head trial, REDEFINE 4, sharpens the caution: against tirzepatide 15 mg in 809 adults with obesity over 84 weeks, CagriSema produced substantial weight loss (23.0% under the efficacy estimand) but did not meet its pre-specified noninferiority margin versus tirzepatide — real efficacy, just not enough to close the gap with the strongest GLP-1/GIP competitor.[6]
The honest bottom line
CagriSema works: pairing amylin and GLP-1 agonism produces large, real weight loss across the REDEFINE Phase 3 trials, in people with and without diabetes. The honest framing is that it landed as a strong combination rather than the runaway leap some expected — the dosing-uptake detail matters, and the long-term outcomes question is still open. As emerging Phase 3 evidence, it is genuinely promising; as a settled verdict, it is not there yet.